Suppr超能文献

长效制剂策略在治疗 PSED 中用于蛋白质和肽类药物的递释。

Long-acting formulation strategies for protein and peptide delivery in the treatment of PSED.

机构信息

Department of Pharmaceutics, Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat 382481, India.

Department of Pharmaceutics, Bharti Vidyapeeth Deemed University, Poona College of Pharmacy, Pune, Maharashtra 411038, India.

出版信息

J Control Release. 2022 Oct;350:538-568. doi: 10.1016/j.jconrel.2022.08.040. Epub 2022 Sep 2.

Abstract

The invigoration of protein and peptides in serious eye disease includes age-related macular degeneration, choroidal neovascularization, retinal neovascularization, and diabetic retinopathy. The transportation of macromolecules like aptamers, recombinant proteins, and monoclonal antibodies to the posterior segment of the eye is challenging due to their high molecular weight, rapid degradation, and low solubility. Moreover, it requires frequent administration for prolonged therapy. The long-acting novel formulation strategies are helpful to overcome these issues and provide superior therapy. It avoids frequent administration, improves stability, high retention time, and avoids burst release. This review briefly enlightens posterior segments of eye diseases with their diagnosis techniques and treatments. This article mainly focuses on recent advanced approaches like intravitreal implants and injectables, electrospun injectables, 3D printed drug-loaded implants, nanostructure thin-film polymer devices encapsulated cell technology-based intravitreal implants, injectable and depots, microneedles, PDS with ranibizumab, polymer nanoparticles, inorganic nanoparticles, hydrogels and microparticles for delivering macromolecules in the eye for intended therapy. Furthermore, novel techniques like aptamer, small Interference RNA, and stem cell therapy were also discussed. It is predicted that these systems will make revolutionary changes in treating posterior segment eye diseases in future.

摘要

严重眼病中蛋白质和肽的激活包括年龄相关性黄斑变性、脉络膜新生血管、视网膜新生血管和糖尿病性视网膜病变。由于大分子如适体、重组蛋白和单克隆抗体的分子量高、降解快、溶解度低,将其递送到眼球后段是具有挑战性的。此外,它需要频繁给药以进行长期治疗。长效新型制剂策略有助于克服这些问题并提供更好的治疗效果。它避免了频繁给药,提高了稳定性、高滞留时间,并避免了突释。这篇综述简要阐述了眼部后节疾病的诊断技术和治疗方法。本文主要关注最近的先进方法,如玻璃体内植入物和注射剂、静电纺丝注射剂、3D 打印载药植入物、基于纳米结构薄膜聚合物装置封装细胞技术的玻璃体内植入物、可注射和储库、微针、载 ranibizumab 的 PDS、聚合物纳米粒子、无机纳米粒子、水凝胶和微球,用于在眼部输送大分子以进行预期治疗。此外,还讨论了适体、小干扰 RNA 和干细胞治疗等新方法。可以预测,这些系统将在未来对治疗眼部后节疾病产生革命性的变化。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验